GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quratis Inc (XKRX:348080) » Definitions » ROCE %

Quratis (XKRX:348080) ROCE % : -34.18% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Quratis ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Quratis's annualized ROCE % for the quarter that ended in Mar. 2024 was -34.18%.


Quratis ROCE % Historical Data

The historical data trend for Quratis's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quratis ROCE % Chart

Quratis Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
Get a 7-Day Free Trial -305.04 -37.19 -33.56 -68.60 -33.49

Quratis Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.33 -43.07 -43.80 -13.83 -34.18

Quratis ROCE % Calculation

Quratis's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-13680.836/( ( (64492.978 - 36549.389) + (66844.126 - 13097.012) )/ 2 )
=-13680.836/( (27943.589+53747.114)/ 2 )
=-13680.836/40845.3515
=-33.49 %

Quratis's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-17116.412/( ( (66844.126 - 13097.012) + (59911.736 - 13514.851) )/ 2 )
=-17116.412/( ( 53747.114 + 46396.885 )/ 2 )
=-17116.412/50071.9995
=-34.18 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quratis  (XKRX:348080) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Quratis ROCE % Related Terms

Thank you for viewing the detailed overview of Quratis's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Quratis (XKRX:348080) Business Description

Traded in Other Exchanges
N/A
Address
306, 13, Teheran-ro 64-gil, Gangnam-gu, Seoul, KOR
Quratis Inc operates as a developer of vaccines and therapies designed to treat tuberculosis. The company develops youth and adults tuberculosis vaccines, messenger ribonucleic acids, and other related immune-related vaccines.

Quratis (XKRX:348080) Headlines

No Headlines